Adaptive Biotechnologies (ADPT) EBIT (2018 - 2025)
Historic EBIT for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $10.3 million.
- Adaptive Biotechnologies' EBIT rose 13153.35% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$78.2 million, marking a year-over-year increase of 6086.34%. This contributed to the annual value of -$162.5 million for FY2024, which is 2840.36% up from last year.
- Per Adaptive Biotechnologies' latest filing, its EBIT stood at $10.3 million for Q3 2025, which was up 13153.35% from -$25.0 million recorded in Q2 2025.
- Adaptive Biotechnologies' 5-year EBIT high stood at $10.3 million for Q3 2025, and its period low was -$71.1 million during Q4 2023.
- Its 5-year average for EBIT is -$44.4 million, with a median of -$47.8 million in 2023.
- As far as peak fluctuations go, Adaptive Biotechnologies' EBIT crashed by 8136.07% in 2023, and later surged by 13153.35% in 2025.
- Quarter analysis of 5 years shows Adaptive Biotechnologies' EBIT stood at -$61.6 million in 2021, then surged by 36.38% to -$39.2 million in 2022, then plummeted by 81.36% to -$71.1 million in 2023, then surged by 52.39% to -$33.8 million in 2024, then skyrocketed by 130.41% to $10.3 million in 2025.
- Its EBIT stands at $10.3 million for Q3 2025, versus -$25.0 million for Q2 2025 and -$29.6 million for Q1 2025.